Exact Sciences Corp logo

Exact Sciences Corp (EXAS)

Market Closed
24 Feb, 20:00
NASDAQ (CM) NASDAQ (CM)
$
103. 45
+0.06
+0.06%
$
19.74B Market Cap
- P/E Ratio
- Div Yield
2,072,097 Volume
-0.85 Eps
$ 103.39
Previous Close
Day Range
103.38 103.67
Year Range
38.81 103.67
Want to track EXAS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
EXAS earnings report is expected in 63 days (29 Apr 2026)
Exact Sciences Corporation (EXAS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Exact Sciences Corporation (EXAS) Presents at Jefferies London Healthcare Conference 2025 Transcript

Exact Sciences Corporation ( EXAS ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:30 AM EST Company Participants Kevin Conroy - Chairman of The Board & CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay. I think we're good to go here.

Seekingalpha | 3 months ago
Exact Sciences Corporation (EXAS) Presents at 7th Annual Healthcare Symposium Transcript

Exact Sciences Corporation (EXAS) Presents at 7th Annual Healthcare Symposium Transcript

Exact Sciences Corporation ( EXAS ) 7th Annual Healthcare Symposium November 14, 2025 8:50 AM EST Company Participants David Harding Conference Call Participants Kevin Dreyer - GAMCO Investors, Inc. Carri Chan Asia Chang Noam Krantz - Guardant Health, Inc. Alexis Tosti Henry Wei George Stoupakis Presentation Kevin Dreyer GAMCO Investors, Inc. All right. Is my mic on?

Seekingalpha | 3 months ago
Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?

Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?

Here is how Exact Sciences (EXAS) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

Zacks | 3 months ago
Earnings Estimates Rising for Exact Sciences (EXAS): Will It Gain?

Earnings Estimates Rising for Exact Sciences (EXAS): Will It Gain?

Exact Sciences (EXAS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks | 3 months ago
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock

Here's Why Exact Sciences (EXAS) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 3 months ago
Exact Sciences (EXAS) is an Intriguing Medical Stock to Watch After Q3 Earnings

Exact Sciences (EXAS) is an Intriguing Medical Stock to Watch After Q3 Earnings

Recognized as a leader in medical diagnostics, the upside potential for Exact Sciences (EXAS) stock has been lifted by its improved operational and financial performance.

Zacks | 3 months ago
Exact Sciences Corporation (EXAS) Q3 2025 Earnings Call Transcript

Exact Sciences Corporation (EXAS) Q3 2025 Earnings Call Transcript

Exact Sciences Corporation ( EXAS ) Q3 2025 Earnings Call November 3, 2025 5:00 PM EST Company Participants Derek Leckow - Vice President of Investor Relations Kevin Conroy - Chairman of The Board & CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Patrick Donnelly - Citigroup Inc., Research Division Bradley Bowers - Mizuho Securities USA LLC, Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Puneet Souda - Leerink Partners LLC, Research Division Jack Meehan - Nephron Research LLC Daniel Brennan - TD Cowen, Research Division Douglas Schenkel - Wolfe Research, LLC Andrew Brackmann - William Blair & Company L.L.C.

Seekingalpha | 3 months ago
Exact Sciences (EXAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Exact Sciences (EXAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 4 months ago
Is Exact Sciences (EXAS) Outperforming Other Medical Stocks This Year?

Is Exact Sciences (EXAS) Outperforming Other Medical Stocks This Year?

Here is how Exact Sciences (EXAS) and EssilorLuxottica Unsponsored ADR (ESLOY) have performed compared to their sector so far this year.

Zacks | 4 months ago
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term

Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 4 months ago
Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock

Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 4 months ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks | 4 months ago
Loading...
Load More